Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
King of Prussia, Pennsylvania–(Newsfile Corp. – January 15, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company’s […]